Good afternoon. Thank you for joining us for the BioTelemetry First Quarter 2017 Earnings Conference Call. Certain statements during the conference call and question-and-answer period to follow may relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities and Litigation Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future to be materially different from the statements that the company’s executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic Form – report on Form 10-K or 10-Q. We assume no duty to update these statements. At this time, all participants have been placed in – on listen-only mode. The floor will be opened for questions and comments following the presentation. It is now my pleasure to turn the floor over to your host, Mr. Joseph Capper. Sir, you may begin.

Thank you, operator, and good afternoon, everyone. I’m Joe Capper, President and CEO of BioTelemetry. As on our previous calls, I’m joined by Heather Getz, our Chief Financial Officer. I’ll start with commentary about our first quarter performance. Heather will take you through a more detailed review of our financial results. I will then provide commentary on how we see the business continuing to evolve in 2017 and beyond, especially in light of our recently announced offer to acquire LifeWatch. After our prepared remarks, we will open up the call for questions. Let’s get started. I’m extremely pleased to report this afternoon that we started out the New Year the same way we exited 2016, with another record setting quarter, during which we surpassed all expectations, posting our 19th consecutive growth period. This performance is even more note worthy, given the first quarter is typically our most challenging, especially in terms of EBITDA and cash, due to certain front-end loaded expenses. You will also recall that on our last call, we stated our intention to invest more heavily in certain growth drivers, like sales and marketing and our digital population health initiative, all of which is occurring according to plan. As a benefit of our consistent performance over the past several years, we are able to make these growth enhancing investments, while still maintaining a solid financial position. Clearly, we intend to continue to drive this high-growth agenda for this foreseeable future, as evidenced by the announcement to acquire LifeWatch, which is in keeping with the guiding principles that shape our operating strategy. As a reminder, those principles include going deeper and wider in cardiac monitoring in order to expand our leadership positions, continuing to build a leading research services business by expanding our service offerings, and identifying other markets…

Thank you, Joe, and good afternoon, everyone. As Joe just announced, the first quarter of 2017 marked our 19th consecutive quarter of year-over-year revenue growth, with total revenue of $55.9 million, which was at the high-end of our expectations. This represents a 15% increase as compared to the first quarter of 2016. Healthcare revenue was strong with an increase of $1.4 million, resulting from strength in volume across all products, as well as a favorable product mix. Partially offsetting these positive drivers was the lower Medicare rate that became effective January 1, which, as expected, impacted us by about a $1 million. Our research revenue increased $3.9 million, largely due to an increase in imaging revenue from the 2016 VirtualScopics acquisition. To conclude, the Technology segment increased $2 million bolstered by sales of wireless blood glucose monitors through our Telcare division. Moving to gross profit, our margin for the first quarter was 59% versus 63% in the first quarter of 2016. The decline in margin was primarily due to the initial costs associated with launching 6,300 devices into the field to meet demand. The impact of the Medicare rate reduction, as well as the 2016 acquisitions, which carry lower margins than our existing business. Partially offsetting these declines were volume driven efficiencies and favorable product mix. We generated adjusted EBITDA of $10.8 million for the first quarter and a 19.4% return on revenue. This was in line with our expectations and reflects the impact of targeted investments that we have started to make, as well as the Medicare rate reduction. Before moving on to the balance sheet, I want to touch on our adjustments to our GAAP results and remind you of how we are reporting our income tax on a GAAP and adjusted basis. Our total adjustments to our…

Thanks, Heather. As you have just heard, we had a highly successful first quarter, starting 2017 with excellent momentum. Our strategy is yielding the results we expected and the organization continues to broaden its opportunities. To ensure continued success in 2017, we will focus on expanding our comprehensive approach with a full launch of our next-generation MCOT system and the continued market penetration of CardioKey and ePatch. Contracting with additional Anthem subsidiaries and pulling through those services continuing to grow our research services backlog at the accelerated rate we are now experiencing and building out a world-class digital population health management business. In addition to these tactical initiatives, we will continue to work diligently on completing the strategic acquisition of LifeWatch, with the anticipation of closing the transaction by mid-summer. As I mentioned, when we made the announcement a few weeks ago, the proposed acquisition of LifeWatch is wholly consistent with a key tenant of our corporate strategy. We believe the acquisition will bolster our growth momentum and improve our ability to expand within and beyond cardiac monitoring market. Additionally, the merger will yield significant synergies over the next 12 to 18 months, creating the opportunity to dramatically accelerate our strategic plan. We are confident we can achieve the synergy objectives, given our in-depth understanding of the cardiac monitoring space. To illustrate the potential, assuming the transaction had occurred on January 1, 2017 and full synergies have been realized immediately, the combined 2017 adjusted EBITDA would be approximately $95 million to $100 million. As you can see, this deal makes great sense both strategically and financially for our shareholders. The combined company will represent the most comprehensive connected health platform in the world, providing an immense benefit to the healthcare system, as we bring more advanced solutions to the market.…

Thank you. [Operator Instructions] Our first question comes from the line of Bruce Jackson with Lake Street Capital. Your line is open.

Hi, good afternoon, and thanks for taking my questions. First, on the LifeWatch acquisition. Can you give us a little bit more detail in terms of like what are the next major milestones and regulatory hurdles that you have to get over and when might those occur?

So the next big one for us is to get HSR approval, we’ve filed for that and we expect that approval around the mid-May timeframe. We’ll then or shortly before that started the first tender period. And obviously, we are hoping to get as much of the shareholder vote in the first tender period as possible. And we think the market has responded well to both – on both sides, both their share price and our share pace, obviously. So and we think the market is understanding some of the potential here. So they’re the next big wicket. So if we can get through regulatory and then requisite shareholder acceptance, we should be in pretty good shape.

Okay, great. And then in terms of the extended-wear Holter monitor, you’ve been getting some traction of that. I know that the reimbursement is still fairly new. How are you finding the reimbursement trends in that particular market segment? And how is the year-over-year reimbursement increase for those devices?

So I think we’re finding a lot of opportunity in terms of where we can sell the product and we’re – I think more and more, we’re able to add the product one, two existing contracts. One of the benefits we have is, we have all the contracted relationships. So our challenge is to go back and add this product line as many places as possible at a rate it’s acceptable. The Medicare rate is obviously quite high, it’s not nationally priced at this point. So we’re – we get a little bit nervous about what happens to that rate in the future. As you know from our past experience, until the product is nationally covered and nationally priced, it’s a bit more subject to volatility. But we’re – so far we’re doing pretty good with it. Our unit volume is obviously very, very high several 100%, because we are coming off of such a low base over the prior year. But I think that the rates are coming in pretty much as we expected, or maybe even a little bit better.

Okay. Last question for Heather just a housekeeping question on the unit volume growth trends. What was the overall healthcare services unit volume growth? And then can I ask if the number is true for MCOT and for the Holter service and monitoring?

Yes. So the overall volume growth was just north of 5% with MCOT and Holter slightly higher than that and even slightly lower.

Okay, great. Thank you very much.

Yes, you’re welcome.

Bruce, we didn’t anticipate huge volume growth in the first quarter, because we’re comping off of a really tough Q1 last year. I think, MCOT was like 18% [Multiple Speakers]

18%, yes.

So it was – we knew that was going to be our toughest comp on a quarterly basis and we were actually glad to see that we’ve got the growth we anticipated and we have plenty of demand, that’s for sure.

Yes, we exited…

Okay, great.

As we exited the quarter, demand was on a rise.

Our highest quarterly volume ever, yes.

Great. Thanks.

Thanks, Bruce.

Our next question is from the line of Marco Rodriguez with Stonegate Capital. Your line is open.

Good afternoon, guys. Thank you for taking my questions.

Hi, Marco.

Hey, a couple of quick housekeeping items. I’m not sure if I caught this, but did you say that there was an incremental $2 million in revenue from Telcare in the product segment, did I catch that?

Yes. The product segment increased by about $2 million. And that was mostly related to the sale of Telcare product, yes.

Okay. Mostly related, so not the full incremental was Telcare. Gotcha. And in terms of Telcare, are you still expecting the annualized $5 million revenue kind of run rate for this fiscal year?

Yes, I mean, we’re – it’s a place Holter, because we – it’s a brand new business. We got to see how it develops. I think…

[Multiple Speakers]

Yes, I think it will be a little choppy early on, but I think we’ll do that or probably more.

Gotcha. And how is the integration coming along with Telcare?

Good, good, really good. We – it’s really exciting from a business standpoint, we have a lot of activity with potential new customers and some pretty large ones that we hope to be able talk about in the coming quarters.

Gotcha. And then coming back here to your – the beta trials on the new MCOT system. Can you talk a little bit about that in terms of timing, when you expect to kind of have those beta trials completed? And any other sort of timing in terms of the launch of the patch version?

Probably full launch third quarter, we’ll probably use the rest of the second quarter to kind of finish up the beta work and get the final development work finished. And then I would say, probably Q3 – probably Q3, we’ll probably have more or full launch of the product.

Gotcha, okay. Then switching here just to kind of a high-level question, if I might, maybe you could talk a bit about the competitive environment. How you’re kind of looking at it today? And if you kind of compare and contrast that environment to perhaps last year at this time? And lastly, how you kind of see that environment developing through fiscal 2017?

So, I think, it’s still a very competitive market. As you know, there has been several new entrants to the market, in some cases sponsored by really deep pockets. And one of the larger competitors is profundus [ph] and that’s partly owned by Merck and partly owned by Boston Scientific. As you know, Medtronic has entered this space with an MCP product and implantable loop of quarter and they’ve had a lot of focus on that. We’ve talked a bit about iRhythm there. They’ve sort of created the extended-wear market. We’re fast follower into that that market, and they have stated their intention of expanding their product portfolio. There is several other smaller players that are in the market. I think, my guess is, you’re going to continue to see these new entrants and some of these more established players invest in the category makes a lot of sense, it’s a very good category. I would say the barriers to scale are pretty significant. We’re the largest and we’ve learned along the way that and each additional kind of level within the business, you learn more about yourself and you learn challenges that you didn’t anticipate. So we have a significant advantage over folks like that, because we’ve experienced a bit of that already. We have 18 years in the space and you learn a lot over that course of time. We have an IP portfolio that’s second to none. We know that we can protect that IP portfolio, we demonstrated that. So we feel pretty good about our position even though it’s a highly competitive market, and I believe it will remain highly competitive. I think, it will stay that way for the foreseeable future. Competition keeps you honest.

Gotcha. And are the competitors still relatively rational at the moment, or anything different in that respect?

Yes, I think, it’s a pretty good competitive set. And as I indicated, the folks that are getting into the marketplace tend to be more sophisticated larger companies.

Got it. And I’m sorry, last quick question. The $1.5 million performance bonus, is there any other anticipated amount in the foreseeable future for that, or we done with that?

Yes, that’s done.

Got it. All right. Thanks a lot, guys.

[Multiple Speakers] It feels like it’s out there.

Yes.

Got it. I appreciate your time, guys. Thanks.

Yes, thank you.

Our next question comes from the line of Mitra Ramgopal with Sidoti. Your line is open.

Yes. Hi, good afternoon. Thanks for taking the questions. Joe, I know, you did mention about Anthem relationship. I was just wondering if there are some other opportunities out there for you, as you look to expand your peer base?

Yes, I would say that there’s still a handful of the Blue’s within individual Blue’s within the network that we would like to get contract with and like to get more favorable coverage policy. They’re probably the biggest remaining ones. I think, it was important to get Anthem that changes their position means that a lot of the other Blue’s take their signal from them. And then, obviously, we continue to work with the association – Blue’s association as well, but the biggest ones are there. In that month, such that we’ll have about all the payer coverage we can get, and important thing is making sure we have all of our current products and new products on those contracts as we get them and even in the existing contracts. So I mentioned getting the extended-wear Holter added to the contract. And then eventually, we’ll leverage those relationships to expand the digital PHM platform as well. That – remember, that’s a product line that sold almost exclusively into the payer environment. So part of the thing we did – one of things we did this year is start to invest a little bit more in a smaller, but experienced sales and marketing team to focus on fair market and to prepare that that market for these additional services that we’ll be bringing to market in the near future.

Okay, thanks. And again, I know, you’re still early in the process, but given the uncertainty over healthcare right now in terms of potential replacement, et cetera, do you think that’s actually holding things back a little in terms of healthcare peers, maybe wanted to take a wait-and-see approach?

I don’t know. I don’t want to hypothesize on that that.

No, I’ll say it again.

I’d say another politic, Mitra.

But at least, they’re not something, yes, that’s keeping you also to speak worrying about?

No, not really.

Right. So I had just some housekeeping items. I know you had mentioned the three non-recurring adjustments, I was just wondering in terms of the line items, where I should be taking that out off?

Sure. So the – actually in the back of the earnings release, there’s a nice little chart. But if you look at the stock-based comp, that’s in G&A…

Right.

The other charges are mainly in – are in one line item, that’s on the P&L.

The other charges?

Yes. So because that’s like the diligence related to LifeWatch that $1.7 million and then the $2.5 million is in – is below operating income.

Okay.

That was an income before taxes, but not an income from operations.

Right. Okay, perfect. And then, Joe, just a quick question also on the digital population health initiative. Obviously, it’s still early, but based on what you’re seeing, I know, diabetes was just the initial area for you, but I take it – is probably want to wait-and-see LifeWatch get close and maybe some more of Telcare before considering expansion there?

I would, yes. Obviously, when you’re making an investment like the one we’re making in LifeWatch, it becomes priority number one to make sure that we integrate that properly, maximize customer retention, and achieve the synergies that we forecasted. So that we have that done properly. We’ve made the investment in Telcare. We own that business, so we’ll continue to nurture it. We have made an investment in a congestive heart failure start-up, I think sales to potentially bring in at some point down the road. And we’ve looked at the other chronics like COPD in asthma and sleep. But there’s – there are some interesting connected health or type of solutions that are being developed. We just can’t do it all at one-time. We just got to make sure we what we do and want to do right.

Okay. Sounds, great. Thanks again for taking the questions.

Thank you.

Thanks, Mitra.

Our next question comes from the line of Gene Mannheimer with Dougherty & Company. Your line is open.

Thanks. Good afternoon, and congrats on a good quarter. Yes, I was hoping you could share a little bit more about the debut with ePatch, when did that launch? What’s the early reception looking like, or are you able to maybe share with us your thoughts on number of patients that will be treated? And maybe distinguish it from the ZIO Patch that’s out in the market for us? Thanks.

Yes. So we are going to have two products in that market right, the CardioKey, which is a lead wire lightweight product that has been in the market for a little while now, because after 14 days the ePatch device again is an extended-wear product is. It’s in a Patch format only. The feedback is really, really good. I mean, we’ve only had it out for a short period of time since the end of March and it’s just limited in scope. So that we can really get great feedback. So we’re not really talking about how many patients we have one it. But the feedback has been exceptionally high. When you look at it compared to some other products out there, one of the major benefits is that, you can reuse the sensor. You can take it out of the patch to slap in assembly and you could run it – you could put it into a new patch. So you can use more than one patch during the same monitoring recession and then certainly you can easily reprogram the sensor to be set up for a new patient. So over time, it will have a lot of flexibility. So one of the other things we’re looking at is, given these devices the capability, say, we downloaded in a doctor’s office. If you know the algorithm product is a male back product. So it extends the turnaround time of the device. We’re going to give the doctors’ flexibility to download in the office, so they have a quicker turnaround time to get the results back in a more timely fashion. So they’re kind of the areas that we’re looking at. If you want to go longer that that product today goes does not go all we haveto14 days if you want to go out thus far then we would recommend the CardioKey product. And again, that’s another product that we’re – in the future will have the capability to download in the doctor’s office, huge benefit.

Yes, that’s interesting. Thanks. And then other question would be around the LifeWatch transaction. Do you have any preliminary thoughts on the likelihood that will clear the SHR review?

I don’t want to take a guess. I mean, we feel pretty good about it, and our advisors feel pretty good about it.

Okay, all right. Pretty good. Thank you.

Thanks, Gene..

Thank you. And I’m not showing any further questions. I’ll now turn the call back over to Mr. Capper for closing remarks.

Thanks, everybody. Again, thank you for your continued support and interest in the company. We will speak to you next quarter. That concludes today’s call.

If you join the conference late today, you may listen to the conference call via digital replay, which will be available through the Investor information section of the BioTelemetry website at www.gobio.com until Wednesday May 17th. Ladies and gentlemen, this does conclude the program. You may now disconnect. Everyone have a great day.